참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Hippuric Acid | HCID 464 | — |
| 반응물 | Triethylamine | HCID 8471 | — |
| 반응물 | 1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide | HCID 15908 | — |
| 반응물 | 1-Hydroxybenzotriazole | HCID 75771 | — |
| 반응물 | {[1-(4-Chlorobenzyl)piperidin-4-yl]methyl}amine | HCID 18426145 | — |
| 용매 | Dichloromethane | HCID 6344 | — |
| 생성물 | 4-[(N-benzoylglycyl)amino]methyl-1-(4-chlorobenzyl)piperidine | HCID 18426192 | 125% |
반응 단계
Hippuric acid (38 mg, 0.21 mmol), EDCI (48 mg, 0.24 mmol), HOBt (31 mg, 0.23 mmol) and triethylamine (38 μL, 0.27 mmol) were added to a dichloromethane (1 mL) solution of 4-(aminomethyl)-1-(4-chlorobenzyl)piperidine (50 mg, 0.21 mmol). The resulting reaction mixture was shaken at 25° C. for 16 hours, then diluted with 1 mL of dichloromethane, washed with a 2 M aqueous solution of NaOH (0.75 mL×2), dried (over MgSO4), concentrated and purified by chromatography (SiO2, 6-8% methanol/dichloromethane) to thereby afford 4-[(N-benzoylglycyl)amino]methyl-1-(4-chlorobenzyl)piperidine (Compd. No. 458). The resulting compound was treated with TFA to provide a TFA salt (105 mg, 97%). The purity was determined by RPLC/MS (85%). ESI/MS m/e 400 (M++H, C22H26ClN3O2).
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US07390830B1 |
|---|
| 출처 데이터셋 | uspto-grants-2008_06 |
|---|
| ORD ID | ord-417eb02fb1774d4c84ec57fe787b3474 |
|---|
| 출처 메모 | uspto-grants-2008_06 |
|---|